|Bid||90.98 x 1300|
|Ask||90.98 x 1200|
|Day's Range||90.86 - 91.63|
|52 Week Range||72.05 - 92.64|
|Beta (5Y Monthly)||0.53|
|PE Ratio (TTM)||25.42|
|Earnings Date||Feb 04, 2020|
|Forward Dividend & Yield||2.44 (2.68%)|
|Ex-Dividend Date||Dec 11, 2019|
|1y Target Est||99.06|
The U.S. stock market seems risky now because valuations are rich, as sentiment marches higher. Usually at such extremes, value stocks enter a sustained phase of outperformance — and that’s likely about to happen. “Ignore value at your peril,” says John Linehan, chief investment officer of equity at mutual-fund giant T. Rowe Price Group.
Seattle Genetics' (SGEN) Adcetris registers strong sales in 2019. The company wins an accelerated approval for Padcev to treat urothelial cancer while other pipeline candidates also progress well.
Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the results of a comprehensive study of wellbeing and mental health among U.S. veterinarians, which are critical issues facing the veterinary profession. Conducted in collaboration with the American Veterinary Medical Association (AVMA), the Merck Animal Health Veterinarian Wellbeing Study also examined job satisfaction, compensation, burnout, substance use disorder, cyberbullying and suicide among veterinarians while evaluating potential solutions.
Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest bidding round under China's national bulk-buy program, government officials said late on Friday. Beijing has been pushing forward the program where drugmakers have to go through a bidding process and cut prices low enough to be considered over generic copies and be allowed to sell their products at public hospitals via large-volume government procurement. Some global firms such as AstraZeneca and Merck have already cautioned about intensifying price pressures on their mature brands in the world's second largest drug market, as China expands the usage of the program.
J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.
Amarin (NASDAQ:AMRN) stock has been choppy for the past year, as the price has made multiple attempts to move above the $23-$24 range. However, this has been a stubborn line of resistance, considering the stock price is currently around $20.Source: Pavel Kapysh / Shutterstock.com Despite this, Amarin stock has still been a pretty good bet over the years. After all, the five-year average return is close to 80%.So, what now? Could there be an opportunity with Amarin stock? Well, I think so.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo see why, let's get a brief backgrounder on the company. Founded in 1993, Amarin is one of the leaders in leveraging lipid science and polyunsaturated fatty acids to create pharmaceuticals to improve heart health. The main drug is Vascepa, which has posted robust growth. In the latest quarter, revenues hit $112.4 million, up 103% on a year-over-year basis. This has been due to substantial increases in the number of subscribers and higher levels of prescriptions per prescriber. * 10 Cheap Stocks to Buy Under $10 However, the key for Amarin is that it recently gained FDA approval for wider applications for Vascepa. This decision, ironically enough, came on Friday the 13th last month -- but of course, this really should be a very lucky day. Vascepa's DevelopmentThe new indication and label expansion -- which is the result of a decade of research and development -- is for a therapy to reduce "the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease."Yes, this is kind of medical jargon. But when boiling things down, the new use for Vascepa is a game changer.According to Dr. Deepak Bhatt, an executive director of the Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center, the treatment "represents one of the most important developments in the prevention and treatment of cardiovascular disease since statins…"The market opportunity is enormous, as there -- on average -- one cardiovascular death occurring every 40 seconds in the U.S. Also, the financial costs of cardiovascular disease events are burdensome at about $500 billion a year -- the most costly in the U.S. The CompetitionThere are a myriad of companies trying to do what Amarin has done; that is, using lipid therapies for cardiovascular disease. But, the science has proven quite complex and challenging.Note that there have been some recent examples of Phase 3 trials that shown disappointing results, such as from AstraZeneca (NYSE:AZN) and Acasti Pharma (NASDAQ:ACST). In fact, since December, ACST has plunged from $2.87 to around $0.80 per share.In fact, Cantor Fitzgerald analyst Louise Chen recently wrote after these companies' failures that "AMRN has been the only company in its class with an outcomes study (REDUCE-IT) that has shown a statistically significant benefit in reducing [cardiovascular] disease. We think the news today underscores our view that AMRN is an interesting asset in a consolidating space." Bottom Line On Amarin StockLast week, Amarin issued revised guidance for 2019. Revenues are now expected to range from $410 million to $425 million, which is at or slightly above the upper end of the prior forecast. The company also noted that beyond 2020, Vascepa's total net revenue "will grow to reach multiple billions of dollars" because "the history of other therapies for chronic conditions suggests that growth builds over multiple years."Given this, the growth story should be robust for quite some time. This should also stir up mergers & acquisitions interest from the mega pharma companies like Pfizer (NYSE:PFE), Merck (NYSE:MRK) and even AZN.Let's face it, they need to fill their pipelines with blockbuster drugs -- and these companies certainly have the resources to pay a premium price for Amarin.Tom Taulli is the author of the book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Stocks to Buy Under $10 * 5 Retail Stocks Placer.ai Thinks Can Win Big in 2020 * 6 Cheap Stocks to Buy Under $7 The post Why Amarin Stock Is Poised for a Healthy 2020 appeared first on InvestorPlace.
Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.
The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
DOW UPDATE Powered by strong returns for shares of UnitedHealth and Visa, the Dow Jones Industrial Average is trading up Wednesday afternoon. The Dow (DJIA) is trading 77 points, or 0.3%, higher, as shares of UnitedHealth (UNH) and Visa (V) have contributed around 25% of the index's intraday rally.
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DOW UPDATE Shares of UnitedHealth and Pfizer are posting positive momentum Wednesday morning, sending the Dow Jones Industrial Average into positive territory. The Dow (DJIA) is trading 153 points, or 0.
The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.
DOW UPDATE Shares of UnitedHealth and Pfizer are posting positive growth Wednesday morning, propelling the Dow Jones Industrial Average into positive territory. Shares of UnitedHealth (UNH) and Pfizer (PFE) are contributing to the index's intraday rally, as the Dow (DJIA) is trading 78 points, or 0.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Merck & Co., Inc. New York, January 14, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Merck & Co., Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee
Nektar (NKTR) agrees to a new joint development plan with Bristol-Myers to include two new registrational studies to evaluate bempegaldesleukin plus Opdivo in bladder cancer and adjuvant melanoma.
FDA Accepts Regulatory Submission of sNDA for LYNPARZA as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer & Grants Priority Review
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to provide an update on the previously-announced (Link) top responder (“Remarkable Responder”) in the combination study of its lead candidate, Bria-IMT™, with Incyte’s INCMGA00012, a PD-1 inhibitor. The patient, who had experienced notable tumor shrinkage while on treatment with Bria-IMT™ in combination with the PD-1 inhibitor pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (MRK)], has since transitioned to treatment in combination with INCMGA00012.
The stock market slumped in late trading Friday, struggling to maintain the recent momentum that pushed major indexes to new highs.
Biopharmaceutical company Amarin (NASDAQ:AMRN) released an update to its preliminary 2019 fiscal results several days ago. The company also provided additional guidance for 2020, based on the expected performance of its new cardiovascular drug, Vascepa. In both cases, there is good news for investors who own Amarin stock.Source: Pavel Kapysh / Shutterstock.com However, the launch of the new drug will require a hefty increase in operational expenses for 2020, and that has tempered market reaction somewhat. AMRN stock slid nearly 8% after the news was released, but has since begun to bounce back. Amarin Revises Preliminary 2019 Results, 2020 GuidanceThe FDA approval of Vascepa -- the new fish oil-based drug to treat cardiovascular disease -- is a game changer for Amarin. In the lead up to the approval, Peter Wilson, a professor of medicine at Emory University (and a member of the FDA advisory panel) noted:InvestorPlace - Stock Market News, Stock Advice & Trading Tips"The panel felt very strongly that this fish oil product [Vascepa], taken in addition to statins, reduced cardiovascular disease." That statement and the subsequent FDA approval of Vascepa last December meant that Amarin had to take a look at the books again. On January 7, the company issued revised preliminary results for 2019. It is now expecting to hit or "slightly exceed" 2019 revenue at the upper end of its previous guidance, of between $410 million and $425 million. That would represent a revenue increase of about 85% over 2018. * The Top 15 Stocks to Buy in 2020 It's worth noting that AMRN had originally been expecting 2019 revenue in the $350 million range, but revised that upward in July.In addition, the company issued guidance for 2020. With Vascepa sales ramping up in the U.S., Amarin is calling for revenue of between $650 million and $700 million. The big win for Amarin stock holders is the expectation that this is just the beginning. When Vascepa goes mainstream, AMRN anticipates that revenue for the drug will grow to "multiple billions of dollars."That doesn't quite make Amarin another Merck (NYSE:MRK), but revenue at that level would certainly elevate AMRN's ranking among global pharmaceutical companies. You Have to Spend Money to Make MoneyThe expectation that Vascepa will be raking in billions of dollars in sales seems like nothing but upside for the company and its investors. So, why did the Amarin stock price drop after the updated financial information was released? It appears that the expenditures required to ramp up Vascepa sales have spooked some. The company noted that it is doubling its U.S. sales force from 400 through most of 2019 to 800. The process of hiring, training and paying those additional employees is costly. In addition, Amarin says that because the sales of Vascepa will be tough to predict at first, it is doubling its expenditure on inventory this year compared to last year.Doing so will ensure it will have enough of the new drug on hand to meet demand, even if it surges beyond predicted levels. In addition, the company is upping its spend on promotional and marketing activities.Overall, Amarin estimates operating expenses in 2020 will increase by $200 million to $250 million over 2019. That number may have caused some concern among investors. The result? A drop in Amarin stock rather than the boost you might expect to see from those revised guidance numbers. Outlook for Amarin StockThe market for cardiovascular dugs is enormous, and growing. It's on pace to hit $63.96 billion by 2026 -- up from $47.29 billion in 2018 -- and doctors are looking for new and more effective drugs for treatment. That puts AMRN in a good position, with Vascepa now approved for use. Where is Amarin stock going to end up as a result of the Vascepa rollout? InvestorPlace contributor Chris Lau had a look and found target valuations for AMRN ranging from $29.56 to over $50.No matter how you measure it, at the current price of around $19, Amarin stock -- powered by Vascepa -- has significant upside for 2020.As of this writing, Brad Moon did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The Top 15 Stocks to Buy in 2020 * The 7 Most Important Companies That Didn't Survive the 2010s * 4 Mega-Tech Stocks Reaching for the Sky The post Amarin Stock Bouncing Back After Revised Results and 2020 Guidance appeared first on InvestorPlace.